Jay S Cohen

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Ways to minimize adverse drug reactions. Individualized doses and common sense are key
    J S Cohen
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, USA
    Postgrad Med 106:163-8, 171-2. 1999
  2. ncbi How celecoxib could be safer, how valdecoxib might have been
    Jay S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    Ann Pharmacother 39:1542-5. 2005
  3. ncbi Antidepressants: an avoidable and solvable controversy
    Jay S Cohen
    Departments of Family and Preventive Medicine and Psychiatry, University of California, San Diego, CA, USA
    Ann Pharmacother 38:1743-6. 2004
  4. ncbi Why aren't lower, effective, OTC doses available earlier by prescription?
    Jay S Cohen
    Department of Family and Preventive Medicine, Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    Ann Pharmacother 37:136-42. 2003
  5. ncbi Tablet splitting: imperfect perhaps, but better than excessive dosing
    Jay S Cohen
    Department of Family and Preventive Medicine and Psychiatry, University of California-San Diego, USA
    J Am Pharm Assoc (Wash) 42:160-2. 2002
  6. ncbi High-dose oral magnesium treatment of chronic, intractable erythromelalgia
    Jay S Cohen
    Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA
    Ann Pharmacother 36:255-60. 2002
  7. ncbi Peripheral neuropathy associated with fluoroquinolones
    J S Cohen
    Departments of Family and Preventive Medicine, and Psychiatry, University of California, San Diego, La Jolla, CA, USA
    Ann Pharmacother 35:1540-7. 2001
  8. ncbi Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference
    J S Cohen
    Department of Family and Preventive Medicine, University of California San Diego, La Jolla, USA
    Arch Intern Med 161:880-5. 2001
  9. ncbi Is the sildenafil product information adequate to facilitate informed therapeutic decisions?
    J S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, USA
    Ann Pharmacother 35:337-42. 2001
  10. ncbi Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil
    J S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, USA
    Ann Pharmacother 35:285-8. 2001

Detail Information

Publications16

  1. ncbi Ways to minimize adverse drug reactions. Individualized doses and common sense are key
    J S Cohen
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, USA
    Postgrad Med 106:163-8, 171-2. 1999
    ..Whenever possible, manufacturers should provide a range of doses and breakable tablets to facilitate flexible dosing...
  2. ncbi How celecoxib could be safer, how valdecoxib might have been
    Jay S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    Ann Pharmacother 39:1542-5. 2005
    ..The marketing of strong, one-size-fits-all dosages places patients, physicians, and even manufacturers at unnecessary risk of unwanted events...
  3. ncbi Antidepressants: an avoidable and solvable controversy
    Jay S Cohen
    Departments of Family and Preventive Medicine and Psychiatry, University of California, San Diego, CA, USA
    Ann Pharmacother 38:1743-6. 2004
  4. ncbi Why aren't lower, effective, OTC doses available earlier by prescription?
    Jay S Cohen
    Department of Family and Preventive Medicine, Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    Ann Pharmacother 37:136-42. 2003
    ..Yet, if OTC doses are effective for treating mild symptoms, why weren't these low, often safer doses made available at least by prescription when the drugs were first approved?..
  5. ncbi Tablet splitting: imperfect perhaps, but better than excessive dosing
    Jay S Cohen
    Department of Family and Preventive Medicine and Psychiatry, University of California-San Diego, USA
    J Am Pharm Assoc (Wash) 42:160-2. 2002
  6. ncbi High-dose oral magnesium treatment of chronic, intractable erythromelalgia
    Jay S Cohen
    Department of Family and Preventive Medicine, University of California San Diego, La Jolla, CA, USA
    Ann Pharmacother 36:255-60. 2002
    ..However, results have been variable, possibly because of the limited oral doses achievable due to frequent diarrhea...
  7. ncbi Peripheral neuropathy associated with fluoroquinolones
    J S Cohen
    Departments of Family and Preventive Medicine, and Psychiatry, University of California, San Diego, La Jolla, CA, USA
    Ann Pharmacother 35:1540-7. 2001
    ..To survey cases of fluoroquinolone-associated adverse events that included peripheral nervous system (PNS) symptoms posted on Internet Web sites...
  8. ncbi Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference
    J S Cohen
    Department of Family and Preventive Medicine, University of California San Diego, La Jolla, USA
    Arch Intern Med 161:880-5. 2001
    ..Thus, it is an established tenet to initiate antihypertensive therapy at low doses to avoid ADEs that diminish patients' quality of life and reduce compliance. However, what are the lowest effective doses of antihypertensive drugs?..
  9. ncbi Is the sildenafil product information adequate to facilitate informed therapeutic decisions?
    J S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, USA
    Ann Pharmacother 35:337-42. 2001
    ..Thus, it is vital that the information in the package insert is not only complete, but also as relevant as possible for the great diversity of patients that physicians encounter...
  10. ncbi Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil
    J S Cohen
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, USA
    Ann Pharmacother 35:285-8. 2001
    ..5 months of availability, and to 522 reported deaths after 13 months of availability. To date, no updated information about FDA-reported deaths has emerged, and no comparative analyses have been published...
  11. ncbi Erythromelalgia: new theories and new therapies
    J S Cohen
    Department of Psychiatry, University of California, San Diego, USA
    J Am Acad Dermatol 43:841-7. 2000
    ....
  12. ncbi Should patients be given an initial low test dose of sildenafil?
    J S Cohen
    Department of Psychiatry, University of California, San Diego, La Jolla 92093, USA
    Drug Saf 23:1-9. 2000
    ....
  13. ncbi Do standard doses of frequently prescribed drugs cause preventable adverse effects in women?
    Jay S Cohen
    Department of Family and Preventive Medicine, University of California in San Diego, USA
    J Am Med Womens Assoc 57:105-10, 114. 2002
    ..The findings in this article suggest that women, especially elderly women, may be prone to adverse effects linked to unnecessarily high drug doses...
  14. ncbi Should rosuvastatin be withdrawn from the market?
    Jay S Cohen
    Lancet 364:1579; discussion 1579-80. 2004
  15. ncbi Transdermal therapy for erythromelalgia
    Jay S Cohen
    Arch Dermatol 142:1508. 2006
  16. ncbi Statin therapy after stroke or transient ischemic attack
    Jay S Cohen
    N Engl J Med 355:2368; author reply 2370-1. 2006